This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
December 01, 2020
Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin[®] in Diffuse Large B Cell Lymphoma
December 01, 2020
Targovax announces impressive objective responses as well as effects on non-injected lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients
November 30, 2020
Over 20,000 Patients Treated with the Non-Surgical Zephyr Valve for Severe Emphysema, a Form of COPD
November 30, 2020
Strong CERAMENT data published in Science Advances
November 30, 2020
Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
November 30, 2020
Nordic Nanovector announces change of its Oslo Børs ticker symbol to “NANOV”
November 24, 2020
Strongbridge Biopharma plc Announces Publication of Secondary Endpoints Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in the Journal, Pituitary
November 24, 2020
Targovax demonstrates encouraging survival data for ONCOS-102 in mesothelioma
November 19, 2020
SynOx Therapeutics raises €37M in Series A Financing
November 19, 2020
INTERIM REPORT Q3 2020